Research published in Rheumatology and autoimmunity challenge the assumption that achieving clinical remission is sufficient in rheumatoid arthritis and show that patient-reported outcomes vary widely by drug class even when disease activity is comparable.
Researchers found that patients taking TNF inhibitors reported better energy levels, mood, and mental well-being than those taking older conventional drugs, while IL-6 and JAK inhibitors showed particular benefits for patients’ physical function. These differences persisted even after accounting for how well the underlying inflammation was controlled.
This study provides real-world evidence that different drug classes offer distinct benefits across quality of life domains, supporting a more nuanced, patient-centered treatment selection approach rather than a one-size-fits-all strategy.
”Despite achieving clinical remission, rheumatoid arthritis patients may experience symptoms such as fatigue, sleep disturbances, and mental or communication problems compared to healthy individuals, highlighting the importance of evaluating patient-reported outcomes as a comprehensive measure of treatment effectiveness.” writes the author.
The researchers noted that this study comes at a time when regulators are calling for patient-reported outcomes to be formally incorporated into drug approvals and reimbursement decisions, and when artificial intelligence-based tools are beginning to use multiple data streams to match the right drug to the right patient.
sauce:
Reference magazines:
DOI: 10.1002/rai2.70048. https://onlinelibrary.wiley.com/doi/10.1002/rai2.70048
